Department of Pharmacy - Center for Drug Research
Office: B 4.072
Since breast cancer is the most frequent cause of cancer death in women worldwide, our group aims to inhibit breast tumor growth and metastasis by using novel therapeutic agents isolated from different natural sources, e.g. myxobacteria and plants.
By inhibiting diverse molecular targets (ranging from the cytoskeleton to fatty acid metabolism), these compounds serve both as chemical tools to decipher the important signaling pathways leading to progression of breast cancer and, moreover, as promising lead structures of modern anticancer drugs.
Successful cancer therapy is often limited by the development of cancer cell resistance to chemotherapeutic agents, mainly due to deregulated pro- and anti-apoptotic pathways.
Thus, another main aspect of our research focuses on the identification and characterization of new classes of chemosensitizers and their targets to avoid or overcome the mechanism of chemoresistance. We aim to elucidate their mode of action and therapeutical impact by using different cell-based, molecular and proteinbiochemical methods as well as in vivo studies.
(Cooperation with the Group of Stephan Sieber TUM, target fishing)
Finally we are member of the NIM excellence cluster with the focus on Biomedical Nanotechnologies. In cooperation with the groups of Ernst Wagner and Thomas Bein (Stefan Wuttke) we test smart nanocarriers for drug delivery with respect of their effects on tumor cells.
An up-to-date list of Dr. Braig's publications can be found on PubMed.